(Q44156054)

30 November 2017

1 reference

title

Experimental human challenge infections can accelerate clinical malaria vaccine development (English)

1 reference

30 November 2017

0 references

1 reference

1 reference

1

Robert W Sauerwein

1 reference

30 November 2017

2

Meta Roestenberg

1 reference

30 November 2017

Vasee S Moorthy

3

1 reference

30 November 2017

publication date

1 January 2011

1 reference

Nature Reviews Immunology

30 November 2017

published in

1 reference

30 November 2017

volume

11

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

57-64

1 reference

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes

30 November 2017

cites work

1 reference

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

21 January 2018

1 reference

Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally

21 January 2018

1 reference

Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite

31 March 2020

1 reference

Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs

31 March 2020

1 reference

The expanding vaccine development pipeline, 1995-2008.

31 March 2020

1 reference

Changes in the burden of malaria in sub-Saharan Africa

31 March 2020

1 reference

Infection with chloroquine-resistant Plasmodium falciparum in man: prepatent periods, incubation periods, and relationships between parasitemia and the onset of fever in nonimmune persons

31 March 2020

1 reference

Human malaria parasites in continuous culture

31 March 2020

1 reference

Complete in vitro maturation of Plasmodium falciparum gametocytes

31 March 2020

1 reference

Plasmodium falciparum gametocytes from culture in vitro develop to sporozoites that are infectious to primates

31 March 2020

1 reference

Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum

31 March 2020

1 reference

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

31 March 2020

1 reference

Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge

31 March 2020

1 reference

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

31 March 2020

1 reference

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

31 March 2020

1 reference

The RTS,S malaria vaccine

31 March 2020

1 reference

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

31 March 2020

1 reference

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

31 March 2020

1 reference

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

31 March 2020

1 reference

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

31 March 2020

1 reference

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

31 March 2020

1 reference

A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period

31 March 2020

1 reference

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

31 March 2020

1 reference

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

31 March 2020

1 reference

Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update

31 March 2020

1 reference

Cardiac complication after experimental human malaria infection: a case report

31 March 2020

1 reference

Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR.

31 March 2020

1 reference

Molecular monitoring in malaria vaccine trials

31 March 2020

1 reference

Mathematical model of the first wave of Plasmodium falciparum asexual parasitemia in non-immune and vaccinated individuals.

31 March 2020

1 reference

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

31 March 2020

1 reference

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

31 March 2020

1 reference

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

31 March 2020

1 reference

Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value.

31 March 2020

1 reference

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

31 March 2020

1 reference

Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors

31 March 2020

1 reference

Protection against a malaria challenge by sporozoite inoculation

31 March 2020

1 reference

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

31 March 2020

1 reference

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum

31 March 2020

1 reference

Malaria and urbanization in central Africa: the example of Brazzaville. Part II: Results of entomological surveys and epidemiological analysis

31 March 2020

1 reference

An estimation of the number of malaria sporozoites ejected by a feeding mosquito

31 March 2020

1 reference

Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice

31 March 2020

1 reference

Feeding behaviour and sporozoite ejection by infected Anopheles stephensi

31 March 2020

1 reference

Quantitation of malaria sporozoites transmitted in vitro during salivation by wild Afrotropical Anopheles

31 March 2020

1 reference

Imaging movement of malaria parasites during transmission by Anopheles mosquitoes.

31 March 2020

1 reference

A Technique for the Inoculation of Known Numbers of Sporozoites as an Aid to Malaria Research

31 March 2020

1 reference

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

31 March 2020

1 reference

Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial

31 March 2020

1 reference

Ethics of vaccine research.

31 March 2020

1 reference

Innate immunity to malaria

31 March 2020

1 reference

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

31 March 2020

1 reference

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

31 March 2020

1 reference

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults

31 March 2020

1 reference

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein

31 March 2020

1 reference

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

31 March 2020

1 reference

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

31 March 2020

1 reference

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

31 March 2020

1 reference

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

31 March 2020

1 reference

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

31 March 2020

1 reference

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

31 March 2020

1 reference

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial

31 March 2020

1 reference

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

31 March 2020

1 reference

Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites

31 March 2020

1 reference

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

31 March 2020

1 reference

Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites

31 March 2020

1 reference

12 December 2020

Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans

1 reference

12 December 2020

Early activity in sporozoite-induced Plasmodium falciparum infections

1 reference

12 December 2020

Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals

1 reference

12 December 2020

Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites

1 reference

12 December 2020

Experimental Proof of the Mosquitomalaria Theory

1 reference

12 December 2020

Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A

1 reference

12 December 2020

Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes.

1 reference

12 December 2020

Experimental malaria in human volunteers: ethical aspects.

1 reference

12 December 2020

Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction

1 reference

12 December 2020

Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine

1 reference

12 December 2020

Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines

1 reference

12 December 2020

Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75.

1 reference

12 December 2020

Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant

1 reference

12 December 2020

Human immunization with attenuated sporozoites

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI2902

1 reference

30 November 2017

1 reference